Kelly McKenna Taulbee
Primary Care · Hamilton, OHNPI 1558974022
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 922 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,932, 2.5 times the $1,552 reported in 2021. Among primary care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 922 payments — averaging $13.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$2K
- Novo Nordisk$1K
- Lilly USA, LLC$729
- Antares Pharma, Inc.$673
- Bayer$542
- plus $5K from 46 others
What the payments were for
- Food & beverage$12,281100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,281 in reported general payments places this provider in the 95th percentile of 321 primary care providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 86 | $108,557 |
| FarxigaDapagliflozin Propanediol | 70 | $87,155 |
| MounjaroTirzepatide | 37 | $49,702 |
| EliquisApixaban | 52 | $47,531 |
| VraylarCariprazine Hcl | 32 | $46,021 |
| JardianceEmpagliflozin | 39 | $37,032 |
| XareltoRivaroxaban | 27 | $34,042 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $27,003 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $25,637 |
| RybelsusSemaglutide | 17 | $17,102 |
| InvokanaCanagliflozin | 15 | $16,839 |
| EntrestoSacubitril/Valsartan | 23 | $16,386 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $13,783 |
| TrintellixVortioxetine Hydrobromide | 19 | $13,661 |
| Repatha SureclickEvolocumab | 12 | $11,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,169 | $125,659103 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $1,639 | $118,720111 claims |
| Johnson & JohnsonXarelto, Invokana | $141 | $50,88142 claims |
| Lilly USA, LLCMounjaro | $729 | $49,70237 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $235 | $47,85454 claims |
| PfizerEliquis | $473 | $47,53152 claims |
| AbbVieVraylar | $2,043 | $46,02132 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $379 | $40,78656 claims |
| NovartisEntresto | $45 | $16,38623 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $120 | $13,66119 claims |
| Astellas Pharma US IncMyrbetriq | $180 | $5,98312 claims |
| Sanofi-aventis U.S. LLCLantus | $12 | $1,84315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 321 primary care providers in Ohio.
Other primary care in Hamilton
- Adine EdwardsSpringfield$14K
- Lindsay ChappellFairlawn$11K
- Laura HolligerNorth Canton$10K
- Caitlyn FrantzDayton$10K
- Brandy RichardsCleveland$8K
- Regan HeagenFindlay$8K
- Zachary HaleBeavercreek$7K
- Katherine ElliotWesterville$7K
- Stephanie EmmettMayfield Heights$7K
- Joseph PriceColumbus$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.